Dennis Brittany B, Roshanov Pavel S, Bawor Monica, Paul James, Varenbut Michael, Daiter Jeff, Plater Carolyn, Pare Guillame, Marsh David C, Worster Andrew, Desai Dipika, Thabane Lehana, Samaan Zainab
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada; Population Genomic Program, Chanchalani Research Centre, McMaster University, Hamilton, Canada.
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada.
Pain Physician. 2016 Jan;19(1):E181-95.
Chronic pain is implicated as a risk factor for illicit opioid use among patients with opioid addiction treated with methadone. However, there exists conflicting evidence that supports and refutes this claim. These discrepancies may stem from the large variability in pain measurement reported across studies.
We aim to determine the clinical and demographic characteristics of patients reporting pain and evaluate the prognostic value of different pain classification measures in a sample of opioid addiction patients.
Multi-center prospective cohort study.
Methadone maintenance treatment facilities for managing patients with opioid addiction.
This study includes participants from the Genetics of Opioid Addiction (GENOA) prospective cohort study. We assessed the prognostic value of different pain measures for predicting opioid relapse. Pain measures include the Brief Pain Inventory (BPI) and patients' response to a direct pain question all study participants were asked from the GENOA case report form (CRF) "are you currently experiencing or have been diagnosed with chronic pain?" Performance characteristics of the GENOA CRF pain measure was estimated with sensitivity and specificity using the BPI as the gold standard reference. Prognostic value was assessed using pain classification as the primary independent variable in an adjusted analysis using 1) the percentage of positive opioid urine screens and 2) high-risk opioid use (= 50% positive opioid urine screens) as the dependent variables in a linear and logistic regression analyses, respectively.
Among participants eligible for inclusion (n = 444) the BPI was found to be highly sensitive, classifying a large number of GENOA participants with pain (n = 281 of the 297 classified with pain, 94.6%) in comparison to the GENOA CRF (n = 154 of 297 classified with pain, 51.8%). Participants concordantly classified as having pain according to the GENOA CRF and BPI were found to have an estimated 7.79% increase in positive opioid urine screens (estimated coefficient: 7.79; 95% CI 0.74, 14.85: P = 0.031) and a 4 times greater odds (odds ratio [OR]: 4.10 P = 0.008; 95% CI: 1.44, 11.63) of engaging in a "high risk" level of illicit opioids use. The prognostic relevance of pain classification was not maintained for the additional participants classified by the BPI (n = 143 discordant).
These results suggest that while the BPI may be more sensitive in capturing pain among patients with opioid addiction, this tool is of less value for predicting the impact of pain on illicit opioid use for opioid addiction patients on methadone maintenance treatment. The GENOA CRF showed high predictive ability, whereby patients classified according to the GENOA CRF are at serious risk for opioid relapse. Using the appropriate tool to assess pain in opioid addiction may serve to improve the current detection and management of comorbid pain.
We caution the interpretation of these result since they are still reflective of participants already maintained on an opioid substitution therapy (OST), which can largely differ from patients who drop out of methadone maintenance treatment (MMT) or never seek treatment altogether.
慢性疼痛被认为是接受美沙酮治疗的阿片类药物成瘾患者使用非法阿片类药物的一个风险因素。然而,有相互矛盾的证据支持和反驳这一说法。这些差异可能源于各研究报告的疼痛测量方法存在很大差异。
我们旨在确定报告疼痛的患者的临床和人口统计学特征,并评估不同疼痛分类方法在阿片类药物成瘾患者样本中的预后价值。
多中心前瞻性队列研究。
用于管理阿片类药物成瘾患者的美沙酮维持治疗机构。
本研究纳入了阿片类药物成瘾遗传学(GENOA)前瞻性队列研究的参与者。我们评估了不同疼痛测量方法对预测阿片类药物复发的预后价值。疼痛测量方法包括简明疼痛量表(BPI)以及所有研究参与者在GENOA病例报告表(CRF)中对直接疼痛问题的回答,该问题为“你目前是否正在经历或已被诊断患有慢性疼痛?”以BPI作为金标准参考,通过敏感性和特异性来估计GENOA CRF疼痛测量方法的性能特征。在调整分析中,以疼痛分类作为主要自变量,分别使用1)阿片类药物尿液筛查阳性百分比和2)高风险阿片类药物使用(=50%阿片类药物尿液筛查阳性)作为线性回归分析和逻辑回归分析的因变量,评估预后价值。
在符合纳入标准的参与者(n = 444)中,发现BPI具有高度敏感性,与GENOA CRF相比,BPI将大量GENOA参与者分类为有疼痛(297名被分类为有疼痛的参与者中有281名,94.6%),而GENOA CRF为297名被分类为有疼痛的参与者中有154名(51.8%)。根据GENOA CRF和BPI一致被分类为有疼痛的参与者,其阿片类药物尿液筛查阳性估计增加7.79%(估计系数:7.79;95%置信区间0.74,14.85:P = 0.031),且从事“高风险”水平非法阿片类药物使用的几率高出4倍(优势比[OR]:4.10,P = 0.008;95%置信区间:1.44,11.63)。对于BPI分类的其他参与者(n = 143名不一致者),疼痛分类的预后相关性未得到维持。
这些结果表明,虽然BPI在捕捉阿片类药物成瘾患者的疼痛方面可能更敏感,但该工具对于预测疼痛对接受美沙酮维持治疗的阿片类药物成瘾患者非法阿片类药物使用的影响价值较小。GENOA CRF显示出较高的预测能力,根据GENOA CRF分类的患者有阿片类药物复发的严重风险。使用合适的工具评估阿片类药物成瘾患者的疼痛可能有助于改善当前对合并疼痛的检测和管理。
我们提醒对这些结果的解释,因为它们仍然反映的是已经接受阿片类药物替代疗法(OST)的参与者,这可能与退出美沙酮维持治疗(MMT)或从未寻求治疗的患者有很大不同。